X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will fund the research and development of company's clinical-stage product, including ORIC-533 small molecule inhibitor of CD73, a key node in the adenosine pathway used to resistance to chemotherapy and immunotherapy-based treatment regimens.
Lead Product(s): ORIC-533
Therapeutic Area: Oncology Product Name: ORIC-533
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 22, 2024
Details:
ORIC-944 is a potent and selective allosteric inhibitor of PRC2. It is under phase 1 clinical development for the treatment of metastatic prostate cancer.
Lead Product(s): ORIC-944
Therapeutic Area: Oncology Product Name: ORIC-944
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
ORIC-533 is a highly potent, orally bioavailable small molecule inhibitor of CD73. It is being evaluated under Phase 1 clinical development for the treatment of patients with relapsed/refractory multiple myeloma.
Lead Product(s): ORIC-533
Therapeutic Area: Oncology Product Name: ORIC-533
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
ORIC-114 is a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations non-small cell lung cancer.
Lead Product(s): ORIC-114
Therapeutic Area: Oncology Product Name: ORIC-114
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
The net proceeds will be used to fund the development of ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers.
Lead Product(s): ORIC-114
Therapeutic Area: Oncology Product Name: ORIC-114
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nextech
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 26, 2023
Details:
ORIC-533, is an orally bioavailable small molecule inhibitor of CD73 that has demonstrated more potent adenosine inhibition in vitro compared to an antibody-based approach, and single agent activity in myeloma model systems.
Lead Product(s): ORIC-533,Elranatamab
Therapeutic Area: Oncology Product Name: ORIC-533
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2022
Details:
ORIC-533 is a highly potent, orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy and immunotherapy-based treatment regimens.
Lead Product(s): ORIC-533
Therapeutic Area: Oncology Product Name: ORIC-533
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
In autologous ex vivo assays using bone marrow aspirates from patients with relapsed refractory multiple myeloma, ORIC-533 overcame immune suppression and triggered significant lysis of multiple myeloma cells across all dose levels tested and in a dose-responsive manner.
Lead Product(s): ORIC-533
Therapeutic Area: Oncology Product Name: ORIC-533
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
The results demonstrate that single agent ORIC-533 potently inhibits the adenosine pathway, which restores anti-tumor immunity and therefore holds potential as a treatment for patients with multiple myeloma.
Lead Product(s): ORIC-533
Therapeutic Area: Oncology Product Name: ORIC-533
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
Results demonstrate that the ORIC-533, small molecule CD73 inhibitor potently inhibits the adenosine pathway, which restores anti-tumor immunity and therefore holds potential for patients with multiple myeloma.
Lead Product(s): ORIC-533
Therapeutic Area: Oncology Product Name: ORIC-533
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
